Nusinersen Production Cost Reports

The report provides a detailed analysis essential for establishing a Nusinersen production plant. It encompasses all critical aspects necessary for Nusinersen production, including the cost of Nusinersen production, Nusinersen plant cost, Nusinersen production costs, and the overall Nusinersen production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Nusinersen production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Nusinersen is an antisense oligonucleotide therapy that treats all types of spinal muscular atrophy (SMA) in pediatric and adult patients. It attaches to a bad spot in the backup SMN2 gene message that normally blocks good assembly. By blocking those blockers, it lets the full key part get included, making usable SMN protein to replace what's missing from the broken SMN1 gene, which harms nerves and muscles.

It shows significant improvements in motor function milestones, survival without ventilation, and event-free survival across presymptomatic. Its common side effects are lower and upper respiratory infections (pneumonia, bronchitis), fever, constipation, headache, vomiting, back pain, post-lumbar puncture headache, runny nose, etc.

The market for Nusinersen is driven by rising spinal muscular atrophy (SMA) cases through expanded newborn screening and genetic testing. The increased awareness, along with growing healthcare investments in developing regions, contributes to its market. Its long-term efficacy in improving motor function and survival across SMA types boosts its demand as a better alternative.

Also, regulatory approvals, label expansions, and healthcare provider preference for targeted treatments fuel its market.  The industrial Nusinersen procurement is affected by managed entry agreements, risk-sharing deals based on clinical outcomes, and payer negotiations. Also, its oral convenience, emerging myostatin inhibitors, and better administration impact its sourcing.

Raw Material for Nusinersen Production

According to the Nusinersen production plant project report, the key raw materials used in the production of Nusinersen include 2'-MOE phosphoramidite monomers, tetrazole activator, and phenylacetyl disulfide sulfurising agent.

Production Process of Nusinersen

The extensive Nusinersen production cost report consists of the following major industrial production process:

1. From Solid-Phase Phosphoramidite Synthesis: The Nusinersen production uses a solid-phase phosphoramidite synthesis. The reaction takes place in a controlled-pore glass support using 2'-O-methoxyethyl-modified ribonucleoside phosphoramidite monomers. This assembles the 18-mer antisense sequence targeting SMN2 intron 7 through iterative coupling, sulfurisation for phosphorothioate linkages, capping, and oxidation cycles. This is followed by deprotection, enzymatic digestion of truncated chains, anion-exchange and reverse-phase chromatography purification to get Nusinersen as the final product.

Nusinersen has the molecular formula of C234H323N61Na17O128P17S17 and a molecular weight of around 7501 Da for its sodium salt. It has full phosphorothioate backbone substitutions and 2'-O-2-methoxyethyl ribose modifications across five positions flanking a central DNA gap to confer nuclease resistance. Its polyanionic charge contributes to its aqueous solubility and high binding affinity to SMN2 pre-mRNA targets. It appears as a white to off-white lyophilised powder or sterile intrathecal solution. It requires refrigerated storage at 2-8 degree Celsius protected from light to preserve higher-order structure stability assessed via circular dichroism spectroscopy. It produces diastereomeric mixtures from 17 PS chiral centres, exhibits low CSF protein binding (<25%) versus plasma (>94%).